138 related articles for article (PubMed ID: 34954918)
1. Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?
Veisman I; Yablecovitch D; Kopylov U; Eliakim R; Ben-Horin S; Ungar B
Isr Med Assoc J; 2021 Dec; 23(12):788-793. PubMed ID: 34954918
[TBL] [Abstract][Full Text] [Related]
2. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.
Ungar B; Haj-Natour O; Kopylov U; Yavzori M; Fudim E; Picard O; Loebstein R; Lahat A; Maor Y; Avidan B; Lang A; Weiss B; Chowers Y; Eliakim R; Ben-Horin S
Medicine (Baltimore); 2015 May; 94(18):e673. PubMed ID: 25950682
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
[TBL] [Abstract][Full Text] [Related]
5. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR
Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852
[TBL] [Abstract][Full Text] [Related]
6. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
9. Development of a C1q-immobilized (Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease.
Yoshimura N; Yokoyama Y; Sako M; Aoyama N; Hirai F; Sawada K; Kashiwagi N; Suzuki Y
Cytokine; 2019 Aug; 120():54-61. PubMed ID: 31003189
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease.
Chi LY; Zitomersky NL; Liu E; Tollefson S; Bender-Stern J; Naik S; Snapper S; Bousvaros A
Inflamm Bowel Dis; 2018 May; 24(6):1344-1351. PubMed ID: 29718278
[TBL] [Abstract][Full Text] [Related]
11. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
Scaldaferri F; D'Ambrosio D; Holleran G; Poscia A; Petito V; Lopetuso L; Graziani C; Laterza L; Pistone MT; Pecere S; Currò D; Gaetani E; Armuzzi A; Papa A; Cammarota G; Gasbarrini A
PLoS One; 2017; 12(10):e0186575. PubMed ID: 29073159
[TBL] [Abstract][Full Text] [Related]
12. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
Vande Casteele N; Khanna R; Levesque BG; Stitt L; Zou GY; Singh S; Lockton S; Hauenstein S; Ohrmund L; Greenberg GR; Rutgeerts PJ; Gils A; Sandborn WJ; Vermeire S; Feagan BG
Gut; 2015 Oct; 64(10):1539-45. PubMed ID: 25336114
[TBL] [Abstract][Full Text] [Related]
13. Intermittent Appearance of Antibodies to Infliximab Is Not Associated With Reduced Efficacy in Patients With Inflammatory Bowel Diseases.
Awadie H; Waterman M
J Clin Gastroenterol; 2022 Jan; 56(1):e47-e51. PubMed ID: 33252556
[TBL] [Abstract][Full Text] [Related]
14. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
[TBL] [Abstract][Full Text] [Related]
15. The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab.
Tun GSZ; Robinson K; Marshall L; Wright A; Thompson L; Wild G; Sargur R; Brooks AJ; Hale MF; Chew TS; Lobo AJ
Eur J Gastroenterol Hepatol; 2022 Mar; 34(3):295-301. PubMed ID: 35100176
[TBL] [Abstract][Full Text] [Related]
16. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
Dreesen E; Van Stappen T; Ballet V; Peeters M; Compernolle G; Tops S; Van Steen K; Van Assche G; Ferrante M; Vermeire S; Gils A
Aliment Pharmacol Ther; 2018 Feb; 47(3):346-355. PubMed ID: 29226370
[TBL] [Abstract][Full Text] [Related]
17. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
[TBL] [Abstract][Full Text] [Related]
18. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
19. Infliximab therapy intensification upon loss of response: Is there an optimal trough level?
Ungar B; Ben-Shatach Z; Ben-Haim G; Yavzori M; Picard O; Fudim E; Kopylov U; Veyrard P; Del Tedesco É; Paul S; Eliakim R; Ben-Horin S; Roblin X
Dig Liver Dis; 2019 Aug; 51(8):1106-1111. PubMed ID: 30928420
[TBL] [Abstract][Full Text] [Related]
20. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
Fiorino G; Ruiz-Argüello MB; Maguregui A; Nagore D; Correale C; Radice S; Gilardi D; Allocca M; Furfaro F; Martínez A; Danese S
Inflamm Bowel Dis; 2018 Feb; 24(3):601-606. PubMed ID: 29462398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
